AR057643A1 - Lacosamida para terapia adjunta - Google Patents

Lacosamida para terapia adjunta

Info

Publication number
AR057643A1
AR057643A1 ARP060100304A ARP060100304A AR057643A1 AR 057643 A1 AR057643 A1 AR 057643A1 AR P060100304 A ARP060100304 A AR P060100304A AR P060100304 A ARP060100304 A AR P060100304A AR 057643 A1 AR057643 A1 AR 057643A1
Authority
AR
Argentina
Prior art keywords
lacosamide
therapy
attached
attached therapy
antipsychotics
Prior art date
Application number
ARP060100304A
Other languages
English (en)
Inventor
Thomas Stohr
Original Assignee
Sanol Arznei Schwarz Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP05001843A external-priority patent/EP1688137A1/en
Application filed by Sanol Arznei Schwarz Gmbh filed Critical Sanol Arznei Schwarz Gmbh
Publication of AR057643A1 publication Critical patent/AR057643A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Uso de una clase de compuestos péptidos para la prevencion, alivio y/o tratamiento de una enfermedad tratada con antipsicoticos, en particular psicosis, más particularmente, esquizofrenia, en una terapia adjunta a al menos un antipsicotico.
ARP060100304A 2005-01-28 2006-01-27 Lacosamida para terapia adjunta AR057643A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64741005P 2005-01-28 2005-01-28
EP05001843A EP1688137A1 (en) 2005-01-28 2005-01-28 SPM 927 for add-on therapy of schizophrenia

Publications (1)

Publication Number Publication Date
AR057643A1 true AR057643A1 (es) 2007-12-12

Family

ID=36636204

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060100304A AR057643A1 (es) 2005-01-28 2006-01-27 Lacosamida para terapia adjunta

Country Status (12)

Country Link
EP (1) EP1841417A2 (es)
JP (1) JP2008528532A (es)
KR (1) KR20070096058A (es)
AR (1) AR057643A1 (es)
AU (1) AU2006208630B2 (es)
BR (1) BRPI0607043A2 (es)
CA (1) CA2595330A1 (es)
EA (1) EA015566B1 (es)
IL (1) IL183973A0 (es)
MX (1) MX2007009070A (es)
NO (1) NO20074361L (es)
WO (1) WO2006079547A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101466390B (zh) * 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
EP1873527A1 (en) 2006-06-30 2008-01-02 Schwarz Pharma Ag Method for identifying CRMP modulators
EP1920780A1 (en) * 2006-10-12 2008-05-14 Schwarz Pharma Ag Peptide compounds for the treatment of hyperexcitability disorders
US8735356B2 (en) 2006-06-15 2014-05-27 Ucb Pharma Gmbh Anticonvulsant combination therapy
US20100260716A1 (en) 2007-10-23 2010-10-14 Ucb Pharma Gmbh Compounds for treating demyelination conditions
US20100151021A1 (en) * 2008-12-16 2010-06-17 Venkatesh Gopi M Compositions Comprising Melperone
EP2468261A1 (en) 2010-12-02 2012-06-27 UCB Pharma GmbH Formulation of lacosamide
JP6027539B2 (ja) 2010-12-02 2016-11-16 ウーツェーベー ファルマ ゲーエムベーハーＵｃｂ Ｐｈａｒｍａ Ｇｍｂｈ ラコサミドの１日１回投与用製剤
ES3001152T3 (es) 2016-12-20 2025-03-04 Lts Lohmann Therapie Systeme Ag Sistema terapéutico transdérmico que contiene asenapina y polisiloxano o poliisobutileno
PL3338768T3 (pl) 2016-12-20 2020-05-18 Lts Lohmann Therapie-Systeme Ag Transdermalny system terapeutyczny zawierający asenapinę
WO2019002204A1 (en) 2017-06-26 2019-01-03 Lts Lohmann Therapie-Systeme Ag TRANSDERMAL THERAPEUTIC SYSTEM CONTAINING ASENAPINE AND SILICONE-TYPE ACRYLIC HYBRID POLYMER
CN118593482A (zh) 2017-12-05 2024-09-06 赛诺维信制药公司 非外消旋混合物及其用途
WO2019113084A1 (en) 2017-12-05 2019-06-13 Sunovion Pharmaceuticals Inc. Crystal forms and production methods thereof
EP3810099A1 (en) 2018-06-20 2021-04-28 LTS Lohmann Therapie-Systeme AG Transdermal therapeutic system containing asenapine
AU2019291060B2 (en) 2018-06-20 2024-09-05 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
MX2021014774A (es) 2019-06-04 2022-02-03 Sunovion Pharmaceuticals Inc Formulaciones de liberacion modificada y usos de las mismas.
US11278634B1 (en) 2021-02-12 2022-03-22 Extrovis Ag Stable parenteral composition of lacosamide

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378729A (en) * 1985-02-15 1995-01-03 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
US5773475A (en) 1997-03-17 1998-06-30 Research Corporation Technologies, Inc. Anticonvulsant enantiomeric amino acid derivatives
EP1243262B1 (en) 2001-03-20 2006-05-31 Schwarz Pharma Ag Novel use of a peptide class of compound for treating non-neuropathic inflammatory pain
DE60100055T2 (de) 2001-03-21 2003-07-24 Schwarz Pharma Ag Neue Verwendung einer Klasse von Peptidverbindungen zur Behandlung von Allodynie oder andere Arten von chronischen oder Phantomschmerzen

Also Published As

Publication number Publication date
CA2595330A1 (en) 2006-08-03
EA015566B1 (ru) 2011-10-31
EA200701594A1 (ru) 2008-02-28
BRPI0607043A2 (pt) 2009-08-04
WO2006079547A2 (en) 2006-08-03
EP1841417A2 (en) 2007-10-10
AU2006208630B2 (en) 2011-09-29
IL183973A0 (en) 2008-12-29
KR20070096058A (ko) 2007-10-01
JP2008528532A (ja) 2008-07-31
NO20074361L (no) 2007-10-26
AU2006208630A1 (en) 2006-08-03
WO2006079547A3 (en) 2006-09-21
MX2007009070A (es) 2007-09-12

Similar Documents

Publication Publication Date Title
CL2007002384A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de la psoriasis.
CL2007002327A1 (es) Compuestos derivados de fenil-imidazol sustituido; composicion farmaceutica; y uso en el tratamiento del vhc.
CL2008001076A1 (es) Compuestos derivados de sulfonamida; composicion farmaceutica; y uso en el tratamiento del cancer.
JO3235B1 (ar) مركبات بيررولوبيريميدين و استعمالاتها
NO20053051D0 (no) Utmattingsreduserende middel.
CL2009001099A1 (es) Uso de una muteina de interleuquina-2 humana para el tratamiento y/o prevencion de una enfermedad autoinmune.
BRPI0719345A2 (pt) Di-hidroimidazóis substituídos e seu uso no tratamento de tumores.
CL2008000910A1 (es) Proteina de fusion que comprende una proteina que corta el peptido beta amiloide; composicion farmaceutica que la comprende, y su uso para prevenir y/o tratar enfermedades relacionadas con el peptido beta amiloide.
CL2007002380A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento terapeutico y/o profilactico de la queratosis actinica.
CL2007000595A1 (es) Compuestos derivados de piperidina; composicion farmaceutica y uso para el tratamiento y/o profilaxis de enfermedades seleccionadas entre hipertension, insuficiencia cardiaca congestiva e insuficiencia renal entre otras.
FR2864552B1 (fr) Traitement de surface par hydroxysulfate
CL2007003643A1 (es) Composicion farmaceutica de azimilidina que comprende 0,5% a aproximadamente 2,5% (w/w) de agua; y uso para el tratamiento de arritmias cardiacas.
EA200701594A1 (ru) Лакозамид для дополнительной терапии
WO2008028963A3 (en) Calreticulin for its use as a medication for the treatment of cancer in a mammal
UY28344A1 (es) Nuevos compuestos
AR058173A1 (es) Uso de sdf-1 para el tratamiento y/o prevencion de enfermedades neurologicas
CL2008000865A1 (es) Compuestos derivados de benzimidazol-2-ona; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de un trastorno psicotico o un deterioro cognitivo.
DE10394003D2 (de) Textilbehandlungsmittel
TW200637538A (en) Lacosamide for add-on-therapy
UY29417A1 (es) Agentes endoparasiticidas
DK1838716T3 (da) Olanzapinpamota-dihydrat
ATE404725T1 (de) Textilbehandlung
RU2005119153A (ru) Средство лечения острой лучевой болезни
ITTV20050186A1 (it) Lettino per l'abbronzatura del corpo.
EP1908467A4 (en) Herpesvirus-derived therapeutic agent for pain

Legal Events

Date Code Title Description
FA Abandonment or withdrawal